There are significant opportunities for new mechanisms and modalities in the global pain medicine market.[6] As of January 2026, there were 590 drugs in development for pain indications (excluding migraine-only drugs), with 32% of them in advanced stages.[6] The pain therapeutics market was valued at USD 88.19 billion in 2025 and is projected to grow to USD 91.54 billion in 2026 to reach USD 127.78 billion by 2035 at a CAGR of 3.78%.[1] Growth is fueled by an aging population, an increase in chronic diseases, accidents, surgeries and investment in research.[1] North America dominates the market due to high incidence of chronic disorders, while Asia Pacific is growing fastest due to investments and generics.[1] The pain management devices market was valued at USD 3,768.6 million in 2024 and is projected to grow to USD 5,835.8 million by 2029 at a CAGR of 9.1%.[2] Chronic pain affects approximately 1.5 billion people worldwide.[2]